Table 4. Demographic and laboratory data of study group 2.
| Feature | non-cirrhotic PBC (n = 24) | cirrhotic PBC (n = 21) |
|---|---|---|
| Age (years) | 51.6 ± 10.9 | 56 ± 9 |
| Gender (F/M) | 24 (100%)/0 (0%) | 17(81%)/4(19%) |
| UDCA treatment (yes/no) | 9 (37.5%)/15 (62.5%) | 21(100%)/0 (0%) |
| Cirrhosis (yes/no) | 0 (0%)/24 (100%) | 21 (100%)/0 (0%) |
| Liver fibrosis stage at biopsy | N/A | |
| F≤1 | 13 (54.2%) | |
| F2 | 7 (29.2%) | |
| F3 | 4 (16.7%) | |
| F4 | 0 (0%) | |
| ALT (IU; normal: <30) | 110.5 ± 148.9 | no data |
| AST (IU/l; normal: <30) | 66.1 ± 60.4 | 175 ± 128 |
| ALP (IU/l; normal: <120) | 250.8 ± 176.6 | 477 ± 296 |
| GGT (IU/l; normal: <42) | 439.6 ± 690.6 | no data |
| Bilirubin (mg/dl; normal:<1) | 1.4 ± 2.0 | 9.1 ± 8.2 |
| Albumin(g/dl; normal:3.8–4.4) | 4.0 ± 0.4 | no data |
| PT (s; normal: 13–17) | 12.7 ± 0.9 | no data |
| Mayo Risk Score for PBC | 4.7 ± 1.5 | no data |
Values are given as mean ± SD, unless stated otherwise.
Abbreviations: UDCA – ursodeoxycholic acid, PBC-primary biliary cirrhosis.